Most doctors meet clinical research twice: when a patient asks about a trial they found, and when someone invites the department to be a site. This is what you need for both — the phases, the obligations that hold wherever a trial runs, what a site actually commits to, and the things patients reliably get wrong.
A patient who says “it is a phase 1 trial” usually does not know that this is the sentence that matters most in the whole conversation.
Is it safe, and at what dose?
The first time a treatment is given to humans. The question is tolerability and dose, not whether it works. Usually healthy volunteers — except in oncology and other serious conditions, where it would be unethical to expose healthy people.
Does it look like it works?
Given to people who have the condition, to look for a signal of benefit and watch short-term safety. Many treatments stop here, which is the point of doing it.
Is it better than what we do now?
The confirmatory study, usually against current standard care or placebo, and usually across many sites. This is the evidence a regulator approves on.
What shows up in the real world?
After approval and in ordinary use. Picks up rarer effects and longer-term outcomes that a trial population of three thousand could never have shown.
Does the generic behave like the original?
Bioavailability and bioequivalence studies, typically single-dose in healthy volunteers. A large share of India's trial activity, and the basis on which a generic is approved.
What happens when nothing is assigned?
Nobody is allocated to a treatment. Care proceeds as it would anyway and data is collected alongside it — registries and cohort studies sit here.
Less than most doctors assume, and the most useful thing you can do takes about ten minutes.
Names and thresholds differ by country. These six obligations do not — and a study that is casual about any of them is telling you something.
This page is written to help a clinician get oriented. It is not legal or regulatory advice, it is not a substitute for reading the rules that apply where you practise, and nothing on it should be relied on for a submission. Where it matters, go to the current text and to your ethics committee.
An independent ethics committee or institutional review board must approve the study before a single participant is enrolled. No regulator anywhere treats this as negotiable, and no legitimate sponsor will ask you to start without it.
ICH-GCP E6 is the common standard across the regions that recognise ICH, and most other countries align to it. It sets what counts as a source document, who may do what, and how data must be recorded.
Written consent on an approved form, in a language the participant understands, taken before any study procedure. Additional safeguards apply for participants who cannot consent for themselves.
Studies are expected to be registered on a public register before the first participant is enrolled — ClinicalTrials.gov, CTRI, EU CTIS, ANZCTR and others. Journals increasingly refuse unregistered trials.
Serious adverse events carry defined reporting timelines to the sponsor, the ethics committee and the regulator. The clock starts when the site becomes aware, not when it is convenient.
A participant may leave at any time without giving a reason, and without it affecting the care they would otherwise receive. This is a condition of approval, not a courtesy.
One jurisdiction properly rather than six shallowly — the shape is easier to recognise elsewhere once you have seen one of them up close.
The rules that govern clinical trials in India, administered through CDSCO. They cover approvals, ethics committee oversight, consent, reporting timelines and compensation.
The approving ethics committee must itself be registered with the national regulator, and the required regulatory permission must be in place before enrolment begins.
Clinical Trials Registry – India expects studies to be registered prospectively, before the first participant is enrolled. It is also the register a doctor or patient can check a study against.
Beyond written consent, the rules require audio-visual recording of the consent process in specified circumstances, including for vulnerable participants.
Where injury or death is related to the trial, the rules require medical management and financial compensation. This is an obligation, not a courtesy, and the process is defined.
India publishes its own GCP guidelines, which sit alongside ICH-GCP E6 rather than replacing it. Studies intended for international filing are generally run to both.
Worth reading before the feasibility questionnaire, not after. None of it is unreasonable; all of it is checkable.
One named doctor is accountable for the conduct of the study at that site, for the safety of the participants, and for everything delegated to the team.
Every task is assigned to a named, trained person before they do it. Most inspection findings are about the gap between what the log says and what happened.
The clinical record is the source. Data entered into a trial database must be traceable back to it — attributable, legible, contemporaneous, original and accurate.
A monitor visits to check consent, eligibility and data against the source. Regulators may inspect. Both assume the paperwork was done at the time, not reconstructed after.
Serious adverse events carry defined reporting timelines to the sponsor, the ethics committee and the regulator. Missing them is a compliance failure regardless of outcome.
Usually said in the first minute, and usually the reason someone declines before they have understood the study.
“You become a guinea pig.”
Participants are monitored far more closely than ordinary care allows — more visits, more tests, a protocol and an ethics committee. Phase 3 usually compares a new treatment against the current standard, not against nothing.
“You might get a sugar pill instead of treatment.”
Placebo alone is rarely used where an effective treatment exists. The common design adds the study drug or placebo on top of standard care, and the consent form must state what is possible.
“It will cost the patient money.”
Study visits, tests and the treatment under study are generally covered by the sponsor, and travel is often reimbursed. No genuine study asks a participant to pay to take part.
“Once you start, you are committed.”
A participant may withdraw at any time, without giving a reason, and without it affecting their usual care. That is a condition of ethics approval.
Trialion Recruit searches the public register for studies recruiting anywhere in the world, in plain language. Free, and nothing anyone types is stored.
Search open studiesTrialion is the EDC your coordinators enter into — forms, edit checks, queries and the audit trail on one data model, connected to the systems you already run.
Talk to us